The U.S. Spirometer Market is projected to grow from USD 317.39 Million in 2025 to USD 1.90 Billion by 2035, while Europe is ...
The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results